<DOC>
	<DOCNO>NCT00174772</DOCNO>
	<brief_summary>Primary Objective : - To evaluate toxicity/safety profile docetaxel/cisplatin induction therapy follow concurrent chemoradiotherapy versus concurrent chemoradiotherapy follow consolidation docetaxel/cisplatin patient locally advance unresectable NSCLC ( stage IIIA- multiple cN2 IIIB ) . Secondary Objective : - To estimate efficacy parameter overall response rate , progression free survival 1 year survival two mention arm .</brief_summary>
	<brief_title>Pulmonart : Docetaxel - Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm NSCLC ( adenocarcinoma , squamous cell carcinoma , large cell carcinoma combination ) Patients must locoregionally advance unresectable NSCLC Stage IIIA multiple level clinical N2 node ( preferably histological cytological confirmation ) . Patients peripheral tumour low lobe contralateral upper mediastinal node station N2 exclude Stage IIIB T4 N3 In T4 category , patient pleural pericardial effusion multiple nodule lobe exclude . Patients T4 disease secondary extensive massive involvement great vessel exclude . Patients exclude expect risk pulmonary toxicity likely high , e.g . V20 excess 35 % . Life expectancy least 12 week . WHO performance status 0 1 . Weight loss ≤ 10 % within last 3 month . Laboratory requirement entry ( within 7 day randomization ) : Blood cell count : Absolute neutrophils ≥ 2.0 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 10 g/dl Renal function : _Serum creatinine ≤1 x upper limit normal ( UNL ) . In case borderline value serum creatinine , 24h creatinine clearance ≥ 60 mL/min Hepatic function : Serum bilirubin ≤ 1 x UNL ASAT ALAT ≤ 2.5 x UNL Alkaline phosphatase ≤ 5 x UNL . Patients ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . Lung function test entry : FEV1 : ≥ 50 % x Normal value DLco : ≥ 50 % x Normal value . Adequate cardiac function . Patient either measurable and/or nonmeasurable lesion ( accord RECIST criterion ) . Exclusion criterion : Diagnosis small cell lung cancer Pregnant lactate woman Patients ( male female ) reproductive potential implementing adequate contraceptive measure Prior systemic chemotherapy , immunotherapy , biological therapy include neoadjuvant adjuvant treatment NSCLC Prior surgery NSCLC , less 5 year study Prior radiotherapy NSCLC History prior malignancy , except cure nonmelanoma skin cancer , curatively treat situ carcinoma cervix cancer curatively treat evidence disease least five year . Symptomatic peripheral neuropathy Grade ≥ 2 except due trauma . Other serious concomitant illness medical condition : Congestive heart failure angina pectoris except medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled hypertension arrhythmia . History significant neurologic psychiatric disorder include dementia seizure . Active infection require IV antibiotic . Active ulcer , unstable diabetes mellitus contraindication corticosteroid therapy . Superior vena cava syndrome contraindicate hydration . Preexisting pericardial effusion . Preexisting symptomatic pleural effusion . Significant gastrointestinal abnormality , include requirement intravenous nutrition , active peptic ulcer disease , prior surgical procedure affect absorption . Distant metastasis . Concurrent treatment experimental anticancer drug . Concomitant within 4week period administration experimental drug investigation . Significant ophthalmologic abnormality . Moderate severe dermatitis . Hypersensitivity docetaxel excipients . Concomitant use phenytoin , carbamazepin , barbiturate , rifampicin . Mental condition render patient unable understand nature , scope , possible consequence study . Patient unlikely comply protocol , i.e. , uncooperative attitude , inability return followup visit , unlikelihood completing study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>